Journal Scans
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
Vandetanib Effective in Advanced Medullary Thyroid Cancer
SA Wells Jr, BG Robinson, RF Gagel, H Dralle, JA Fagin, M Santoro, E Baudin, R Elisei, B Jarzab, JR Vasselli, J Read, P Langmuir, AJ Ryan, MJ Schlumberger
Yes
20110924
2011 Oct 24
J Clin Oncol
Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III Trial
J Clin Oncol. 2011 Oct 24;[Epub Ahead of Print], SA Wells Jr, BG Robinson, RF Gagel, H Dralle, JA Fagin, M Santoro, E Baudin, R Elisei, B Jarzab, JR Vasselli, J Read, P Langmuir, AJ Ryan, MJ Schlumberger
TAKE-HOME MESSAGE
EXPERT COMMENTARY
Abstract
SUMMARY
OncologySTAT Editorial Team
Patients with advanced or metastatic medullary thyroid carcinoma (MTC) have a poor 10-year survival rate, and neither radiotherapy nor chemotherapy has achieved durable objective responses in this population. Nearly all patients with hereditary MTC have germline mutations in the RET (rearranged during transfection) proto-oncogene. About 50% of patients with sporadic MTC have an RET mutation, and 85% have the M918T mutation.Vandetanib is an oral tyrosine kinase inhibitor that targets RET, as well...
